Skip to content

Opus Genetics, Inc.

IRD· NasdaqCore metricsCIK 1228627

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -5.58%
Market cap
$392.42M
96.65M shares
Filings
1,051
$1.14M
Q3 2026+29.1% FY25 yoy
-$46.50M
Q3 2026N/M FY25 yoy
-$19.25M
Q3 2026N/M FY25 yoy
-$38.90M
Q3 2026derivedN/M FY20 yoy
-$0.46
Q3 2026N/M FY25 yoy
$88.97M
Q3 2026+48.7% FY25 yoy
$392.42M
—
49.6×
10.2×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$4.06+106.09%+$2.09past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$14.20MFY 2025
$39.85M0FY 2009FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$14,196,000reported
FY 20242024-12-31$10,992,000reported
FY 20232023-12-31$19,049,000reported
FY 20222022-12-31$39,850,000reported
FY 20212021-12-31$589,000reported
FY 20202020-12-31$0reported
FY 20192019-12-31$3,000,000reported
FY 20132013-12-31$0reported
FY 20122012-12-31$0reported
FY 20112011-12-31$0reported
FY 20102010-12-31$0reported
FY 20092009-12-31$0reported

Capital returns

Dividends and buybacks · FY2009 to FY2011
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2011—$0.00$0.00—95.35M sh+13.3%—
FY2010—$0.00$0.00—84.16M sh——
FY2009—$0.00$0.00————

Pharmaceutical preparations

Opus Genetics, Inc. is the 158th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR